2017-12-05 08:30
Adam has experience in production management and process development. He has worked, among other things, to develop and implement new production methods in ISO13485-certified medical technology companies. Adams previous professional experiences include...
2017-11-23 08:00
Led by Dr Cynthia Ma, the study investigated 50 women with breast cancer treated with standard endocrine therapy in combination with Ibrance® prior to surgery. DiviTum® was used to measure cell proliferation rate in blood samples collected before...
2017-11-21 08:00
The proof of concept study, including 404 patients, provides evidence for using DiviTum as a dynamic biomarker before and during therapy to give important answers regarding prognosis and how effective therapy is. Biovica’s assay was prognostic for...
2017-11-14 08:00
With imaging methods used for evaluating the effect of treatment, it takes about three months to evaluate whether the given therapy is effective or not. The new study demonstrates that DiviTum® accurately can predict outcome (progression free- and...
2017-11-08 09:00
At the conference Mattias will address how novel ways to measure cell proliferation offers new solutions to old challenges in drug development. Enhanced evaluation of drug efficacy by new assays such as DiviTum® can save development time and cost...
2017-11-06 09:00
For more information follow the link https://www.facebook.com/groups/smabolagsjakten/ During the live QA session, you will be given the opportunity to ask questions directly to the company management in Swedish or English. Answers will then be given in...
2017-05-22 14:00
Dr Rotstein received his Ph.D at Karolinska Institutet and has worked as an oncologist for almost 40 years. He was previously Head of Department at the Oncology Clinic at Danderyd Hospital where he together with his colleagues built and managed a highly-appreciated...
2017-05-04 10:00
The value of the order is approximately one million SEK . The order is one of several from the same customer and so far, the second largest Biovica has received. "We are very pleased that leading actors in the industry see the value of our product...
2017-04-11 09:30
Patients in the study are given different standard therapies, meaning that the value of DiviTum® is tested in a significantly larger patient population than what previously has been presented in Biovica breast cancer studies. Results from the study...
2017-04-07 09:00
The drug, a SUMO-ylation inhibitor (SUMOi) developed by the Dutch company UbiQ. Biovica’s DiviTum® technology will be used in pre-clinical models to provide an early signal of cell growth inhibition during development and Biovica’s work...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects